End stage kidney disease required hemodialysis (Prevalence case) super high-flux hemodialysis nutrition assessment RNA sequencing middle molecule uremic toxin protein bound uremic toxin
Conditions
Interventions
All patients receive super high-flux hemodialysis for 12 months
Experimental Device
Sponsors
Faculty of medicine, Naresuan University
Nipro sales (Thailand) CO.,LTD
Eligibility
Sex/Gender
All
Age
19 Years to 90 Years
Inclusion criteria
Inclusion criteria: Age > 18 years old Prevalence case of hemodialysis at least 3 months Hemodialysis 3 times/week with adequate Kt/V > 1.2 Serum albumin > 3 mg/dL Auria Vascular access are eligible for blood flow rate > 400 ml/min Adequate dry weight with BCM +/- OH 2 kg Hemodynamic stability more than 2 weeks Inform consent
Exclusion criteria
Exclusion criteria: Chronic infection or active cardiovascular diseases 3 month prior to recruitment Metastasis malignancy Advance cirrhosis Pregnancy Hemodynamic instability Contraindication to anticoagulant Refuse to informed consent Serum albumin levels < 3 mg/dL
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nutrition assessment Before and after intervention every 3 months Serum albumin levels | — |
Secondary
| Measure | Time frame |
|---|---|
| Nutrition assessment Before and after intervention every 3 months Body composition analysis,Efficacy Before and after intervention every 3 months spKt/V,Efficacy Before and after intervention every 3 months Beta 2 microglobulin,Efficay Before and after intervention every 3 months Kappa light chain,Efficacy Before and after intervention every 3 months Lambda light chain,Albumin loss in dialysate Before and after intervention every 6 months Albumin measure,Efficacy Before and after intervention RNA sequencing in PBMCs | — |
Countries
Thailand
Contacts
Public ContactTheerachai Thammathiwat
Faculty of Medicine, Naresuan University
Outcome results
None listed